RAYMOND LOUIS STALLINGS

Summary

Affiliation: Royal College of Surgeons in Ireland
Country: Ireland

Publications

  1. pmc Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma
    Derek M Murphy
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 6:e21436. 2011
  2. pmc miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs
    Marta Terrile
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 6:e28356. 2011
  3. pmc Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles
    Amanda Tivnan
    Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 7:e38129. 2012
  4. pmc MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome
    J Ryan
    Department of Molecular and Cellular Therapeutics, Cancer Genetics Research Group, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    Br J Cancer 107:967-76. 2012
  5. pmc Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation
    Derek M Murphy
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e8154. 2009
  6. pmc Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival
    Isabella Bray
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e7850. 2009
  7. pmc Expressional alterations in functional ultra-conserved non-coding RNAs in response to all-trans retinoic acid--induced differentiation in neuroblastoma cells
    Karen M Watters
    Cancer Genetics, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
    BMC Cancer 13:184. 2013
  8. pmc MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1
    Laura Creevey
    Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    Mol Cancer 12:23. 2013
  9. pmc Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene
    Maria Meehan
    Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Dublin, Ireland
    Mol Cancer 11:6. 2012
  10. pmc MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2
    Niamh H Foley
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    Mol Cancer 9:83. 2010

Research Grants

  1. MiRNA Expression in Neuroblastoma
    Raymond Stallings; Fiscal Year: 2009
  2. MiRNA Expression in Neuroblastoma
    RAYMOND LOUIS STALLINGS; Fiscal Year: 2010

Collaborators

  • Kenneth Bryan
  • Patrick G Buckley
  • Niamh H Foley
  • Karen M Watters
  • Louis Chesler
  • Pieter Mestdagh
  • Amanda Tivnan
  • Jo Vandesompele
  • Timothy A Chan
  • Frank Speleman
  • Derek M Murphy
  • Maria Meehan
  • Isabella Bray
  • Laura Creevey
  • Jacqueline Ryan
  • J Ryan
  • Marta Terrile
  • Frida Abel
  • Sudipto Das
  • Leah Alcock
  • Suzanne Prenter
  • Isabella M Bray
  • Adnan R Khan
  • Harry Harvey
  • Armida W M Fabius
  • Laavanya Parthasarathi
  • Caroline A Jefferies
  • Niamh Moran
  • A M Davidoff
  • I M Bray
  • J Lynch
  • L Creevey
  • Derek Murphy
  • A O'Meara
  • Elisa Lazzari
  • M Meehan
  • Berenice Ortiz
  • J Fay
  • Hannah Webber
  • Daniel Dalevi
  • REBECKA JORNSTEN
  • Staffan Nilsson
  • Joelle Vermeulen
  • Katleen De Preter
  • Maria Nethander
  • Per Kogner
  • Albert Hallsworth
  • John Maris
  • Lynsey Vaughan
  • Desmond G Higgins
  • Wendy B London
  • Maureen O'Sullivan
  • Anne O'Meara
  • Patrick W McGrady
  • Desmond Higgins

Detail Information

Publications17

  1. pmc Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma
    Derek M Murphy
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 6:e21436. 2011
    ..MeCP2 is a CpG methyl binding protein which has been associated with a number of cancers and developmental disorders, particularly Rett syndrome...
  2. pmc miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs
    Marta Terrile
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 6:e28356. 2011
    ..Here, we evaluate the dysregulation of miRNAs in tumors from TH-MYCN mice that are either wild-type (TH-MYCN) or deficient (TH-MYCN/p53ER(TAM)) for the p53 tumor suppressor gene...
  3. pmc Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles
    Amanda Tivnan
    Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 7:e38129. 2012
    ..These tumors express high levels of the cell surface antigen disialoganglioside GD2 (GD(2)), providing a target for tumor-specific delivery...
  4. pmc MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome
    J Ryan
    Department of Molecular and Cellular Therapeutics, Cancer Genetics Research Group, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    Br J Cancer 107:967-76. 2012
    ..The aim of this study was to explore the independent association of miR-204 with survival in a neuroblastoma cohort, and to investigate the phenotypic effects mediated by miR-204 expression in neuroblastoma...
  5. pmc Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation
    Derek M Murphy
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e8154. 2009
    ..The single most important prognostic indicator of poor clinical outcome in this disease is genomic amplification of MYCN, a member of a family of oncogenic transcription factors...
  6. pmc Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival
    Isabella Bray
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e7850. 2009
    ..MiRNA expression patterns are also predicative of clinical outcome, highlighting the potential for miRNA mediated diagnostics and therapeutics...
  7. pmc Expressional alterations in functional ultra-conserved non-coding RNAs in response to all-trans retinoic acid--induced differentiation in neuroblastoma cells
    Karen M Watters
    Cancer Genetics, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
    BMC Cancer 13:184. 2013
    ..Here, we examine the impact of ATRA treatment on T-UCR expression and investigate the biological significance of these changes...
  8. pmc MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1
    Laura Creevey
    Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    Mol Cancer 12:23. 2013
    ..Our aim was to investigate the potential tumor suppressive role of miR-497 in high-risk neuroblastoma...
  9. pmc Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene
    Maria Meehan
    Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Dublin, Ireland
    Mol Cancer 11:6. 2012
    ..The molecular mechanism, however, by which PTPRD renders a tumor suppressor effect in neuroblastoma is unknown...
  10. pmc MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2
    Niamh H Foley
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    Mol Cancer 9:83. 2010
    ..The purpose of this study was to elucidate the molecular mechanism by which miR-184 conveys pro-apoptotic effects...
  11. pmc A 6-gene signature identifies four molecular subgroups of neuroblastoma
    Frida Abel
    Department of Clinical Genetics, Gothenburg University, Gothenburg, Sweden
    Cancer Cell Int 11:9. 2011
    ..abstract:..
  12. pmc MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma
    Amanda Tivnan
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    BMC Cancer 11:33. 2011
    ....
  13. pmc MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation
    Raymond L Stallings
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    Semin Cancer Biol 21:283-90. 2011
    ..A thorough understanding of miRNA and genetic pathways regulating neuroblastoma cell differentiation potentially could lead to targeted therapies for this disease...
  14. ncbi Therapeutic targeting of miRNAs in neuroblastoma
    Raymond L Stallings
    Royal College of Surgeons in Ireland, Dublin, Ireland
    Expert Opin Ther Targets 14:951-62. 2010
    ..The identification of novel therapeutic targets is urgently required to reduce patient morbidity...
  15. pmc MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics
    R L Stallings
    Royal College of Surgeons and Children s Research Centre Our Lady s Children s Hospital, Dublin, Ireland
    Curr Pharm Des 15:456-62. 2009
    ..The evidence for the contribution of miRNAs in the aggressive neuroblastoma phenotype is reviewed in this article, along with exciting possibilities for miRNA mediated therapeutics...
  16. ncbi MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma
    Amanda Tivnan
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    Anticancer Res 30:4391-5. 2010
    ..Previous studies have shown that miR-184 expression has anti-proliferative effects in neuroblastoma cells grown in culture. Therefore, it was of interest to evaluate this effect in vivo...
  17. ncbi Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma
    R L Stallings
    National Centre for Medical Genetics, Our Lady s Hospital for Sick Children, Crumlin, Dublin, Ireland
    Cytogenet Genome Res 106:49-54. 2004
    ..The possibility that low level gain of distal 2p is a risk factor for high level MYCN amplification is discussed...

Research Grants3

  1. MiRNA Expression in Neuroblastoma
    Raymond Stallings; Fiscal Year: 2009
    ..The identification of such targets, along with the development of reagents that will interfere with their function, is a necessary prerequisite for improving patient survival. ..
  2. MiRNA Expression in Neuroblastoma
    RAYMOND LOUIS STALLINGS; Fiscal Year: 2010
    ..abstract_text> ..